World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
61
Citations
13449
World Ranking
3234
National Ranking
1510

Tibor Keler publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Tibor Keler sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 214 publications — 40th percentile

40% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Tibor Keler D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Tibor Keler sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 61 D-Index — 36th percentile

36% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Tibor Keler is affiliated with Bristol-Myers Squibb in the United States. Their research primarily focuses on medicine, with significant contributions to immunology and microbiology. Keler's work is especially concentrated on oncology and immunology as subfields, with additional involvement in radiology, nuclear medicine, imaging, pulmonary and respiratory medicine, and molecular biology.

Throughout Keler's career, their research topics have included:

  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • CAR-T Cell Therapy Research
  • Monoclonal and Polyclonal Antibodies Research
  • Immune Cell Function and Interaction
  • T-cell and B-cell Immunology
  • Mast Cells and Histamine

Keler has published in various scientific venues, with frequent publications appearing in:

  • Regular and Young Investigator Award Abstracts
  • Cancer Research
  • Allergy
  • Journal of Clinical Oncology
  • Clinical Cancer Research

Notable recent papers include:

  • "Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial," published in Clinical Cancer Research (2020)
  • "Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s," published in Nature Communications (2020)
  • "Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets," published in Nature Cancer (2020)
  • "Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies," published in Blood Advances (2020)
  • "Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study," published in Allergy (2022)

Frequent coauthors collaborating with Keler include:

  • Michael Yellin
  • Laura Vitale
  • Diego Alvarado
  • Lawrence J. Thomas
  • Henry C. Marsh

Best Publications

  • Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

    Marina Caskey;Florian Klein;Julio C. C. Lorenzi;Michael S. Seaman

  • Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma

    Kristin Sanderson;Ronald Scotland;Peter Lee;Dongxin Liu

  • HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

    Johannes F. Scheid;Johannes F. Scheid;Joshua A. Horwitz;Yotam Bar-On;Edward F. Kreider

  • Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

    Marina Caskey;Till Schoofs;Henning Gruell;Allison Settler

  • A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

    James Schuster;Rose K. Lai;Rose K. Lai;Lawrence D. Recht;David A. Reardon;David A. Reardon

  • Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205

    Madhav V. Dhodapkar;Mario Sznol;Biwei Zhao;Ding Wang

  • Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma

    Stephen M. Ansell;Steven M. Horwitz;Andreas Engert;Khuda Dad Khan

  • High-Dimensional Phenotypic Mapping of Human Dendritic Cells Reveals Interindividual Variation and Tissue Specialization.

    Marcela Alcántara-Hernández;Rebecca Leylek;Lisa E. Wagar;Edgar G. Engleman

  • Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells.

    Bithi Chatterjee;Bithi Chatterjee;Anna Smed-Sörensen;Anna Smed-Sörensen;Lillian Cohn;Cécile Chalouni

  • Mannose receptor-targeted vaccines

    Tibor Keler;Venky Ramakrishna;Michael W Fanger

  • Human monoclonal antibodies to her2/neu

    Tibor Keler;Yashwant Deo

  • Circulating precursors of human CD1c+ and CD141+ dendritic cells

    Gaëlle Breton;Jaeyop Lee;Yu Jerry Zhou;Joseph J. Schreiber

  • Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation

    Lillian Cohn;Bithi Chatterjee;Filipp Esselborn;Anna Smed-Sörensen;Anna Smed-Sörensen

  • Dendritic cell‐targeted protein vaccines: a novel approach to induce T‐cell immunity

    C. Trumpfheller;M. P. Longhi;M. Caskey;J. Idoyaga

  • Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques

    Tibor Keler;Ed Halk;Laura Vitale;Tom O’Neill

  • Antigenic targeting of the human mannose receptor induces tumor immunity.

    Li-Zhen He;Andrea Crocker;Janine Lee;Jose Mendoza-Ramirez

  • Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates

    Kavita Tewari;Barbara J. Flynn;Silvia B. Boscardin;Kathrin Kastenmueller

  • Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti–human DEC205 monoclonal antibody

    Cheolho Cheong;Jae Hoon Choi;Laura Vitale;Li Zhen He

  • Mannose Receptor Targeting of Tumor Antigen pmel17 to Human Dendritic Cells Directs Anti-Melanoma T Cell Responses via Multiple HLA Molecules

    Venky Ramakrishna;John F. Treml;Laura Vitale;John E. Connolly

  • Phase I Study Utilizing a Novel Antigen-Presenting Cell–Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients

    Michael A. Morse;Robert Chapman;John Powderly;Kimberly Blackwell

  • Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates

    Barbara J. Flynn;Kathrin Kastenmüller;Ulrike Wille-Reece;Georgia D. Tomaras

Frequent Co-Authors

Nina Bhardwaj
Nina Bhardwaj Icahn School of Medicine at Mount Sinai
Thomas P. Davis
Thomas P. Davis University of Arizona
Paul K. Wallace
Paul K. Wallace Roswell Park Cancer Institute
Marina Caskey
Marina Caskey Rockefeller University
David A. Reardon
David A. Reardon Harvard University
John H. Sampson
John H. Sampson Duke University
Jan G. J. van de Winkel
Jan G. J. van de Winkel Genmab (United States)
Ralph M. Steinman
Ralph M. Steinman Rockefeller University
Michel C. Nussenzweig
Michel C. Nussenzweig Rockefeller University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare fields through online education can open diverse career opportunities. Many students transition into immunology by first gaining clinical experience via accelerated nursing pathways. For example, accelerated NP programs provide a fast-track route to becoming a nurse practitioner, combining advanced clinical skills with patient care knowledge.

If you are new to nursing, online options like online accelerated nursing programs for non nurses offer accessible entry points. These programs are designed to build foundational nursing expertise quickly while allowing flexibility for career changers.

For those aiming to start at the undergraduate level, understanding which universities offer the easiest ABSN to get into can help reduce barriers when pursuing a Bachelor of Science in Nursing. Such programs often provide a streamlined curriculum tailored to students who want a fast educational path.

Similarly, exploring which LPN programs are easiest to get into can assist aspiring Licensed Practical Nurses in finding programs with simpler admission criteria, serving as a stepping stone toward advanced immunology-related roles in healthcare.

Best Scientists Citing Tibor Keler

Trending Scientists

Recently Published Articles